Submitted by Anonymous (not verified) on 22 September 2023 - 13:40
Human medicines European public assessment report (EPAR): Scemblix, asciminib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 25/08/2022, Revision: 3, Status: Authorised
Source: